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PURPOSE. Conjunctival melanoma (CM) is a rare malignant disease that can lead to recurrences
and metastases. There is a lack of effective treatments for the metastases, and we set out to
develop a new animal model to test potential therapies. Zebrafish are being used as a model
for many diseases, and our goal was to test whether this animal could be used to study CM.
METHODS. Three human CM cell lines (CRMM-1 and CM2005.1, which both harbor a B-RAF
mutation, and CRMM-2, which has an N-RAS mutation) were injected into the yolk sac,
around the eye, and into the duct of Cuvier of transgenic (fli:GFP) Casper zebrafish embryos.
Fluorescent and confocal images were taken to assess the phenotype and the behavior of
engrafted cells and to test the effect of Vemurafenib as a treatment against CM.
RESULTS. While the cells that had been injected inside the yolk sac died and those injected
around the eye sporadically went into the circulation, the cells that had been injected into the
duct of Cuvier colonized the zebrafish: cells from all three cell lines proliferated and
disseminated to the eyes, where they formed clusters, and to the tail, where we noticed
extravasation and micrometastases. Vemurafenib, a potent agent for treatment of B-RAF
V600E–positive melanoma, inhibited outgrowth of CRMM-1 and CM2005.1 cells in a
mutation-dependent way.
CONCLUSIONS. The (fli:GFP) Casper zebrafish embryo can be used as an efficient animal model
to study metastatic behavior of human CM cells and warrants further testing of drug efficacy
to aid care of CM patients.
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Conjunctival melanoma (CM) is a rare malignant oculardisease, accounting for 5% to 10% of all human ocular
melanoma.1 Over the past decades, its incidence has increased
worldwide.2–4 The current treatment of choice for primary CM
is wide surgical excision, combined with brachytherapy,
cryotherapy, and topical chemotherapy (e.g., mitomycin C).
However, effective targeted therapies have not yet been
developed to treat this malignancy5; CM’s high recurrence rate
is associated with metastasis and poor prognosis.6–8 Further-
more, the mortality rate is high, ranging from 13% to 38% after
10 years.9–11
In this malignancy, essential mutations occur in the B-RAF
and N-RAS genes.5,12–14 B-RAF mutations constitutively activate
the mitogen-activated protein kinase (MAPK) pathway and its
downstream kinases MEK1/2-ERK1/2, promoting tumor prolif-
eration.15,16
Mice have previously been used as a model to study human
CM,17,18 but there are some limitations. The major disadvan-
tages are a slow growth and spread of the tumor, which can
take weeks to months, and the high cost for reproduction and
housing. The cost increases further when immunosuppressive
drugs are needed to prevent tumor rejection.19 Therefore, there
is a need to find a new animal model.
The zebrafish model has been used widely in research
because of its advantages, such as (1) the fish’s high fecundity
and short time between generations, (2) the high interspecies
conservation of molecular pathways between zebrafish and
mammals,20–22 (3) their transparency, allowing direct imaging
of development, organogenesis, and cancer progression,23
which enables tracking of transplanted cells,24 (4) the
possibility of xenotransplantation, and (5) their permeability
to small molecular weight compounds from water, enabling
easy delivery and efficient screening of large numbers of
anticancer compounds.19 Furthermore, the fact that their
adaptive immune system does not reach maturity until 4-weeks
postfertilization allows them to be used without the need for
immunosuppression in the embryonic stages.20
There are no studies showing whether zebrafish embryos
can be used as an animal model for human CM, and our goal
was to determine if this animal can be used as a screening
platform based on the xenotransplantation of three human CM
cell lines. Our group has shown that two of three available CM
cell lines, CRMM125 and CM2005.1,26 harbor a B-RAF V600E
mutation, while the third, CRMM2, contains an N-RAS Q61L
mutation.17,27 We injected stable red fluorescently labeled
(lentiviral tdTomato-blas) CM cells via different routes into the
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embryonic zebrafish. Thus, we determined the most effective
engraftment strategy for the establishment of CM xenograft
tumors in zebrafish and we observed distinct phenotypes after
implantation of the three CM cell lines. We subsequently
validated the model through the use of the well-known B-RAF
inhibitor, vemurafenib.
MATERIAL AND METHODS
Cell Culture
We used three CM cell lines, CRMM-1, CRMM-2, and
CM2005.1, all generated from recurrent primary CM. The
CRMM-1 and CRMM-2 cell lines, isolated by Nareyeck et al.,25
were cultured in F-12K nutrient mixture, Kaighn’s modification
(Gibco, Life Technologies, Bleiswijk, The Netherlands), sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS;
Greiner Bio-one, Alphen aan den Rijn, The Netherlands) and
1% Penicillin/Streptomycin (Gibco). CM2005.1, established in
2007 by Keijser et al.,26 was cultured in RPMI 1640 Dutch
modified medium (Gibco), supplemented with 10% FBS
(Greiner Bio-one), 1% GlutaMAX, and 1% Penicillin/Streptomy-
cin (Gibco). To generate CM cells with red fluorescence, cells
were stably transduced with lentivirus expressing both tandem
dimer (td)Tomato and Blasticidin-S, as previously described.28
Virus-containing medium was replaced with fresh medium
containing Blasticidin-S (2 lg/mL) to select transduced cells.
Transduction of the cells with the tdTomato-expressing virus
did not alter the growth pattern of parental cells. After
transduction, cells were incubated with multiplicity of
infection (MOI) of 2.0 in medium with 8.0-lg/mL polybrene
for 16 hours. For cultivation of stable transgenic tdTomato-
expressing cells, BLASticidin-S (2 lg/mL) was added to the
complete medium.
Growth Kinetics of Tomato-Red Cells In Vitro
Transgenic tdTomato-expressing cell lines were seeded in
triplicate in 96-well plates at a density of 600, 1200, and 2400
for CRMM-1 and CRMM-2 cell lines in a total volume of 100 lL
of medium. Because the CM2005.1 cell line is smaller than the
others, it was seeded in triplicate in 96-well plates at a density
of 1000, 2000, and 4000 cells per well, in a total volume of 100
lL of medium. For testing vemurafenib, cells were seeded at a
density of 2000 (CRMM-1 and CRMM-2) or 3500 (CM2005.1)
cells per well, in a total volume of 100-lL medium. Cell
proliferation was analyzed at 1, 3, and 5 days of incubation by
an In-Cell Western assay (Odyssey Infrared Imaging System, LI-
COR, Leusden, The Netherlands): after removing the medium,
cells were fixed for 1 hour in 4% formaldehyde and incubated
with DRAQ5, a far-red fluorescent DNA dye (1:8000, DR50050;
Biostatus Ltd., Loughborough, UK). After washing with 0.1%
Tween-PBS buffer, plates were scanned with an Odyssey
Infrared Imaging System (LI-COR). Odyssey 3.0 software was
used to quantify signal intensity.
Animals and Injection Sites
The (fli:GFP) Casper transgenic zebrafish29 were maintained
according to standard protocols (http://ZFIN.org, in the public
domain) and in compliance with Dutch animal welfare
regulations and European Union Animal Protection Directive
2010/63/EU. Our research followed the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research.
When the cells reached 75% to 90% confluency, they were
trypsinized (0.05% trypsin-EDTA; Gibco), centrifuged for 4
minutes at 200g, washed with Dulbecco’s phosphate-buffered
saline (DPBS; Invitrogen), and diluted to 250 cells/nL in 2%
polyvinylpyrrolidone-40 (PVP-40; Calbiochem, San Diego, CA,
USA).
At 2-days postfertilization (dpf), dechorionated zebrafish
embryos were injected with this CM cell suspension using
glass capillary needles with an opening of approximately 20 to
30 lm. Embryos were anesthetized with 2% tricaine (Sigma-
Aldrich Corp., Zwijndrecht, The Netherlands) and positioned
in a petridish covered with 1% agarose. Using a pneumatic
picopump and a manipulator (World Precision Instruments,
Sarasota, FL, USA), 200 to 400 cells were injected inside the
yolk sac in one group of embryos, or inside the duct of Cuvier
in a second group, and 50 to 100 cells were injected around
the right eye in a third group of zebrafish. The embryos were
each placed individually in a well of a 48-well plate, with 1 mL
of egg water (60-lg/mL OceanSalt in demi water) in each well
and maintained at 348C, which was the optimal temperatures
for cell growth and zebrafish embryo development.30 The egg
water was refreshed daily and the injected embryos were
evaluated at 2-, 4-, and 6-days postinjection (dpi), using a
fluorescence stereo microscope (Leica M205FA; Leica Micro-
systems, Inc., Buffalo Grove, IL, USA).
Kaplan-Meier Survival Analysis of Injected
Embryos
After establishing the optimal injection site for CM cells in
zebrafish, we determined how injection of cancer cells
influenced embryo survival, shown in a Kaplan-Meier survival
analysis (cumulative survival curve). Tumor cells were injected
into the Duct of Cuvier at 2 dpf. One group (n ¼ 90) was
injected with CRMM-1, a second group (n¼ 201) with CRMM-
2, and the third group (n ¼ 221) received an injection with
CM2005.1. A fourth group (n¼121) received an injection with
PVP-40 and the last group (n ¼ 96) was not injected. The
number of injected cells was between 200 and 400 per
embryo. After injection, the embryos were maintained at 348C,
and scored daily for survival, without changing the egg water,
until 6 dpi.
Phenotype of CM Cell Lines in Zebrafish and Cell
Migration
The embryos were injected with CRMM-1, CRMM-2, or
CM2005.1 cells and screened at 1 dpi under the same
conditions as described above. Embryos were anaesthetized
with 2% tricaine at 1, 4, and 6 dpi to perform image analysis
using a fluorescence stereo microscope and a confocal
microscope (Leica TCS SPEl; Leica Microsystems, Inc.). For
cell growth quantification, the pixel numbers that represent
the amount of cells were counted at 1 and 6 dpi, using ImageJ
software.31
Statistical analysis was performed using R version 2.15.1.32
The difference in growth among the three cell lines in the
embryos was analyzed using a generalized linear model (GLM)
with normal distribution after square-root transformation of
the data.
Immunohistochemistry (IHC)
After 6 dpi, injected whole embryos were fixed in 4%
paraformaldehyde and stored in 100% methanol at 208C. To
perform IHC, embryos were rehydrated, washed with PBS-TX,
and permeabilized with 10 lg/mL of protease K in PBS-TX at
378C (in a water bath) for 10 minutes. Then, they were washed
three times using PBS-TX for 10 minutes and put in blocking
buffer at room temperature (RT) for 1 hour. Following this,
whole embryos were incubated with Ki67 rabbit antibody at a
dilution of 1:200 (Abcam, Cambridge, UK), at RT for 2 hours
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and stored overnight at 48C. After that, the embryos were
washed and incubated with the second antibody, Alexa fluor
633 anti-rabbit at a 1:200 dilution (Invitrogen) at RT for 2 hours
and stored overnight at 48C. The immune-stained whole
embryos were arranged on a microplate and covered with
1% low melting agar to take pictures with a confocal
microscope.
Toxicity Test and Treatment With The Inhibitor In
Vivo
For the in vivo toxicity test, 1mL of drug-containing egg water
was put into the wells of a 24-well plate. Six noninjected 3-dpf
zebrafish embryos were placed in each well, maintained at
348C and observed daily until 8 dpf. The drugs were refreshed
every 2 days and all experiments were performed in triplicate.
A drug concentration was considered nontoxic when survival
was equal or higher than 80%.
At 2 dpf, embryos were injected with CRMM-1, CRMM-2,
or CM2005.1 cells and treatment with Vemurafenib was
started at 1 dpi. They were treated for 5 days with the
inhibitor, changing the egg water and inhibitor twice, and
photographed at 1 and 6 dpi using the fluorescence stereo
microscope. Using ImageJ software,31 pixel numbers were
determined.
RESULTS
Growth Kinetics of Tomato-Red Cells In Vitro
Our goal was to establish a CM xenograft model allowing the in
vivo screening of drugs. We used tdTomato-red expressing cells
to track the proliferation and migration of tumor cells in vivo.
To verify the possible adverse effect of tdTomato expression on
cellular growth kinetics, we used an In-Cell Western prolifer-
ation assay. No effect was observed until 5 days of incubation
(Supplementary Fig. S1), indicating that we could use the
tdTomato overexpressing cells in the zebrafish.
Injection Sites
To establish the model, we tested three different injection sites:
engraftment around the eye, in the yolk sack, or in the duct of
Cuvier. The duct of Cuvier is the common cardinal vein formed
by the left and right posterior cardinal veins joining up with
the anterior cardinal vein. The duct of Cuvier functions as an
embryonic vein structure collecting all venous blood and leads
directly to the heart’s sinus venosus; it carries the blood
ventrally across the yolk sac.33 Using this site of injection
ensures a rapid and a near complete dissemination of injected
cancer cells throughout the blood circulation.34
Injecting tumor cells around the eye was technically
challenging because of the small size of the eye, limiting
throughput and increasing lethality. After injecting tumor cells
around the eye, the cells disseminated to the head, inside the
eye, and inside the circulation (Figs. 1A, 1B). Injecting cells
inside the yolk sac was easy to perform, but after 6 dpi, many
cells had died (Figs. 1C, 1D). Injections into the duct of Cuvier
were relatively easy to perform and cells survived and
proliferated (Figs. 1E, 1F).
The injection into the duct of Cuvier ensures that the cells
have access to the endothelium and their intrinsic adhesion
molecules and nutrients and helps to disseminate the cells
throughout the body. As the duct of Cuvier is the most reliable
and biologically relevant injection site, we used this site in all
subsequent experiments. The cumulative survival curves of all
groups were above 80% (Fig. 2).
Phenotype of CM Cells in Zebrafish
After cells had been injected inside the duct of Cuvier,
migration was assessed. With all three cell lines, 10% to 30%
of the embryos had cells inside the eye and between 58% and
64% of embryos showed cells in the tail (Fig. 3). At 1 dpi, cells
from all three cell lines had disseminated to the eye and to the
tail, forming clusters at 4 and 6 dpi, with more prominent
clusters occurring when we used cell line CM2005.1 (Fig. 4).
Cells from all three cell lines grew inside, outside, and around
vessels during the 6 days of observation (Fig. 4). More tumor
FIGURE 1. Stereo fluorescence image of zebrafish embryos engrafted with CM cells (vasculature in green and CM cells in red). The embryos were
injected at 2 dpf with CRMM-1 CM cells labeled with tomato-red (red). Photographs taken of the same embryo that had been injected with CM cells
around the eye at 1 (A) and 6 dpi (B), showing cells inside the head (white arrows) and in the tail (yellow arrow). Following injection in the yolk
sac, an embryo shows the cells in the yolk sac at 1 (C), but not 6 dpi (D). After injection of cells into the duct of Cuvier, cells are seen inside the
circulation at 1 dpi (E), mainly in the tail and inside the eye. The same embryo shows a cluster in the tail and cells inside the eye at 6 dpi (F). The
stereo fluorescent images (original magnification:320) are representative of >10 independent experiments.
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cells were observed at 6 dpi than at 1 dpi (P < 0.001 for
CRMM-1, P ¼ 0.04 for CRMM-2, and P ¼ 0.001 for CM2005.1)
(Fig. 5).
Immunohistochemistry (IHC)
As the image analysis suggested that the cells had divided
inside the zebrafish, we tested this using IHC with the Ki67
antibody at 6 dpi. Some cells from all three CM cell lines
stained positive for Ki67 at 6 dpi and in some cases, mitotic
figures in tumor cells were observed (Fig. 6). These findings
show that the CM cells proliferated 6 days after injection inside
the duct of Cuvier.
Toxicity Test and Treatment With Vemurafenib In
Vivo
Vemurafenib inhibits the proliferation of the CM cell lines in
vitro in a mutation-dependent way (Supplementary Fig. S2) and
was, therefore, used to test the in vivo model. The toxicity test
resulted in 94% survival at 7 and 8 dpf at a concentration of
0.25 lM, and 94% at 8 dpf when the 0.5-lM concentration was
used (Supplementary Fig. S3). For all the other tested
concentrations, survival of the embryos was 100%. As the
drug concentration was considered nontoxic when survival
was equal or higher than 80%, we concluded that vemurafenib
was nontoxic to the zebrafish at the evaluated concentrations.
FIGURE 2. Survival of (fli:GFP) Casper embryos injected with different
types of CM cells, after injection of 200 to 400 cells in the duct of
Cuvier on 2 dpf. The number of embryos were: nCRMM-1¼90, nCRMM-2¼
201, nCM2005.1 ¼ 221, nPVP ¼ 121, and nControl ¼ 96.
FIGURE 3. Location of tumor cells at 6 dpi in (fli:GFP) Casper zebrafish
embryos after injection of 200 to 400 cells of the different CM cell lines
into the duct of Cuvier at 2 dpf. Tumor cell locations were scored using
a stereo fluorescence microscope. The same embryo could harbor cells
in more than one place at the same time. ‘‘Others’’ indicates cancer cell
retention/outgrowth at the base of the heart or in the head region. The
number of embryos used was nCRMM-1¼70, nCRMM-2¼81, and nCM2005.1
¼ 77.
FIGURE 4. Confocal micrographs of the observed phenotypes at 1, 4, and 6 dpi after engraftment of three CM cell lines via the duct of Cuvier in
(fli:GFP) Casper zebrafish embryos. At 1 dpi, CRMM-1 (A), CRMM-2 (D), and CM2005.1 (G) cells were already inside the eye (a1, a2, d1, g1) and in
the tail (a3, d2, g2). At 4 (B, E, H), and 6 dpi (C, F, I), cells formed clusters in the tail and in the eye in all three cell lines (data not shown). The
clusters were more evident in the tail (h2) and in the eye (h1, i1) after injection of cell line CM2005.1. The three cell lines (data not show) grew
inside (a3, b1, d2, e2, g2, h2, i2), outside (b2), and around (c2) the vessels and the cells could be found inside the eye (f1, i1) until 6 dpi. The
images were acquired using a Leica TCS SPE confocal microscope and managed in ImageJ software. Images (A–I)310 dry objective. All the other
images:320 dry objective. Red: cells labeled with tdTomato; green: GFP-endothelial cells of the (fli:GFP) Casper lines.
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Considering that the highest concentrations of vemurafenib
that had been evaluated in vitro were 3.2 lM (CRMM-1 and
CRMM-2) and 0.32 lM (CM2005.1), and that this compound
was nontoxic to the embryos up to a concentration of 4.0 lM,
we chose a final concentration 4.0 lM/mL to treat engrafted
embryos up to 5 dpi because the compound was added in egg
water.
At 5-days post treatment with 4 lM of vemurafenib, we
noticed inhibition of CRMM-1 (Fig. 7A) and CM2005.1 (Fig. 7C)
cell growth when compared with control groups; proliferation
of CRMM-2 was not affected by vemurafenib (Fig. 7B;
vemurafenib treatment versus control P ¼ 0.013 for CRMM-1,
P ¼ 0.007 for CM2005.1, and P ¼ 0.33 for CRMM-2).
DISCUSSION
Our results showed that when CM cells were injected around the
eye (at 2 dpf), they accidentally passed into the circulation and
frequently ended up in the tail, head, and ocular vessels. This is
because there is a complex system of retinal blood vessels in the
zebrafish’s eye and intraocular vessels are already detected at 60-
hours postfertilization.35 The vasculature develops quickly and,
at 5 dpf, reaches from the optic disk to the intraocular lens. This
site of injection is so rich in vessels that it has been used to inject
cells into the circulation in adult zebrafish.36
We believe that the injection in the yolk sac leads to cell
death of the many engrafted cells because the yolk sac is a
lipid-rich environment devoid of blood circulation and sparse
in nutrient and adhesion molecules. Furthermore, some cells
that had been injected in the yolk sac passively migrated to the
embryo’s body (e.g., the tail, the head or inside the eye,
directly after engraftment). This may have occurred because
the cells were inadvertently introduced inside the circulation,
as the duct of Cuvier, the common cardinal vein, crosses the
yolk sac and leads directly to the heart’s venous sinus.33 In
contrast to Haldi et al.,30 who recommended that injections
can be made anywhere in the yolk sac, we believe that the
injections can be done in the yolk sac while avoiding the duct
of Cuvier, but we did not use this approach: our experiments
show that injecting into the Duct of Cuvier led to the most
reproducible results. The model that we used represents a
metastatic disease model, as human CM cells were injected into
the circulation of the zebrafish embryos.37
Using Ki67 staining, we showed that CM cells survived and
proliferated inside the fish until at least 6 dpi. We furthermore
observed that 58% to 64% of all engrafted embryos showed
dissemination of the cells to the tail at 6 dpi, demonstrating a
preference of all three cell lines for this site. We believe that
the reason why these cells ended up in the tail was mainly
because of the presence of the caudal hematopoietic tissue
(CHT) in this site. Myeloid cells have been detected at the
posterior end of the CHT and are involved in the process of
both tumor vascularization and invasion, which are critical
steps toward localized tumor growth and micrometastasis
formation.38 Once the cells have reached the CHT, we believe
that they are arrested there through physical entrapment and
due to a slower blood flow. The CHT harbors numerous stem
cell components driving metastasis formation and prolifera-
tion. The zebrafish embryo can be used to study the interaction
between the innate immune system (neutrophils and macro-
phages) and tumor cell behavior: this is one of the reasons why
we set out to develop this CM model.37,38
The mutations involved in CM are more similar to
cutaneous melanoma than uveal melanoma. Cutaneous mela-
noma and CM harbor a B-RAF mutation, while in most uveal
melanoma, GNAQ/GNA11 mutations occur.39,40 While all three
cell lines were derived from primary tumors and not from
metastases, all of them migrated into the eyes in a considerable
proportion of engrafted zebrafish embryos (30% of CRMM-1,
28% of CRMM-2, 10% of CM2005.1). However, metastatic
cutaneous human melanoma did not migrate to the eyes when
injected into zebrafish embryos.30,41 In a recent study,42
primary and metastatic uveal melanoma cells were seen to
migrate to the eye in 10% of the embryos. This suggests that
the migration of eye cancer cells to the eye is not mutation
dependent, but controlled by others factors, which should be
evaluated in the future.
We determined whether the CM zebrafish model can be
used to test drugs: vemurafenib inhibited the growth of cell
lines CRMM-1 and CM2005.1 in vivo and in vitro, and not of
cell line CRMM-2. The results in vitro were expected as CRMM-
1 and CM2005.1 harbor a B-RAF V600E mutation, while the
CRMM-2 cell line contains an N-RAS Q61L mutation.17,27
Vemurafenib was approved in 2011 by the Food and Drug
Administration for treatment of unresectable melanoma
harboring B-RAF V600E mutations43 and is a potent agent for
FIGURE 5. Outgrowth of CM cells in vivo in (fli:GFP) Casper zebrafish
embryos engrafted with 200 to 400 cells of CM cell lines at 2 dpf via the
duct of Cuvier. Images were taken at 1 and 6 dpi. Each point means one
embryo and the pixel number indicates the amount of fluorescence
cells counted using ImageJ software. Statistical significances were
calculated by general linear model (ANOVA) and P values were as
follows: *P < 0.05, **P < 0.01, ***P < 0.001. For all groups: n ‡ 51.
FIGURE 6. Confocal image of immunohistochemistry with Ki67 in a
whole 6 dpi (fli:GFP) Casper zebrafish embryo. There were 200 to 400
CRMM-1 td-Tomato CM cells injected into the duct of Cuvier. We see
tumor cell (red) migration outside the vessels (green); cell proliferation
is indicated by Ki67 staining (blue). This image of the tail of a live
embryo was acquired by confocal microscope (320 dry objective).
Similar images were obtained from all three CM cell lines in >10
independent experiments.
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treatment of B-RAF V600E-positive melanoma.44 It has been
used to target metastases and a primary CM.45 Vemurafenib
was previously shown to have a selective effect on CM cell
lines in vitro46 and we used that information to validate the
usability of the zebrafish CM model. In our experiments, the
effects of the vemurafenib in the treatment of engrafted
embryos were the same as those observed in vitro showing
that the zebrafish embryo model can be used in drug screens
against human CM.
CONCLUSIONS
The zebrafish model that we describe here allows migration
and proliferation of three human CM cell lines. These cells
induced a phenotype that was highly reproducible when
injected via the duct of Cuvier. The engrafted embryos
tolerated the treatment with vemurafenib well, while this
inhibitor affected the cell proliferation in vivo in a mutation-
dependent manner. Thus, we conclude that the (fli:GFP)
Casper zebrafish embryos can be used as an efficient animal
model to study metastatic behavior of CM cells and for
preclinical testing of new treatments against human CM.
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